JP2022531939A5 - - Google Patents
Info
- Publication number
- JP2022531939A5 JP2022531939A5 JP2021566481A JP2021566481A JP2022531939A5 JP 2022531939 A5 JP2022531939 A5 JP 2022531939A5 JP 2021566481 A JP2021566481 A JP 2021566481A JP 2021566481 A JP2021566481 A JP 2021566481A JP 2022531939 A5 JP2022531939 A5 JP 2022531939A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- agent according
- cancer
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846064P | 2019-05-10 | 2019-05-10 | |
| US62/846,064 | 2019-05-10 | ||
| PCT/GB2020/051140 WO2020229803A1 (en) | 2019-05-10 | 2020-05-11 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531939A JP2022531939A (ja) | 2022-07-12 |
| JP2022531939A5 true JP2022531939A5 (https=) | 2023-05-18 |
Family
ID=70847425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566481A Pending JP2022531939A (ja) | 2019-05-10 | 2020-05-11 | がんを処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11414488B2 (https=) |
| EP (1) | EP3965757A1 (https=) |
| JP (1) | JP2022531939A (https=) |
| CN (1) | CN113993537A (https=) |
| AU (1) | AU2020273615A1 (https=) |
| CA (1) | CA3139035A1 (https=) |
| IL (1) | IL287907A (https=) |
| SG (1) | SG11202112452WA (https=) |
| TW (1) | TWI869398B (https=) |
| WO (1) | WO2020229803A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3400218A4 (en) * | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| CA3037144A1 (en) * | 2016-09-16 | 2018-03-22 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
| EP3544621A1 (en) | 2016-11-27 | 2019-10-02 | BicycleRD Limited | Methods for treating cancer |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US20190389907A1 (en) | 2016-12-23 | 2019-12-26 | Bicycletx Limited | Peptide ligands for binding to mt1-mmp |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| SG11202104356VA (en) | 2018-10-30 | 2021-05-28 | Bicyclerd Ltd | Bt1718 for use in treating cancer |
| WO2020178574A1 (en) | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| WO2021074647A1 (en) | 2019-10-16 | 2021-04-22 | Bicyclerd Limited | Methods for treating cancer |
-
2020
- 2020-05-08 TW TW109115453A patent/TWI869398B/zh active
- 2020-05-11 AU AU2020273615A patent/AU2020273615A1/en not_active Abandoned
- 2020-05-11 EP EP20728125.4A patent/EP3965757A1/en active Pending
- 2020-05-11 WO PCT/GB2020/051140 patent/WO2020229803A1/en not_active Ceased
- 2020-05-11 US US16/871,305 patent/US11414488B2/en active Active
- 2020-05-11 CN CN202080043160.8A patent/CN113993537A/zh active Pending
- 2020-05-11 JP JP2021566481A patent/JP2022531939A/ja active Pending
- 2020-05-11 CA CA3139035A patent/CA3139035A1/en active Pending
- 2020-05-11 SG SG11202112452WA patent/SG11202112452WA/en unknown
-
2021
- 2021-11-08 IL IL287907A patent/IL287907A/en unknown
-
2022
- 2022-07-11 US US17/861,839 patent/US20230025971A1/en not_active Abandoned
-
2023
- 2023-11-17 US US18/513,146 patent/US20240199742A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531939A5 (https=) | ||
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| EP2817011B1 (en) | Treatment of cancer | |
| JP2007515469A5 (https=) | ||
| CA2801309C (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| Powles | Prostaglandins and cancer | |
| US20250177364A1 (en) | Combination therapies for breast cancer | |
| JP2002544231A5 (https=) | ||
| CN102065865A (zh) | 多发性骨髓瘤治疗 | |
| KR20130092617A (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| KR20130118981A (ko) | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 | |
| ES2330324T3 (es) | Derivados del epotilon para el tratamiento del hepatoma y de otros canceres. | |
| TW200412971A (en) | Therapeutic treatment | |
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| JP2011513429A (ja) | 改善された抗癌治療法 | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| JP2703321B2 (ja) | 化学療法的抗腫瘍剤と非ステロイド系抗炎症薬による腹腔内治療 | |
| CA2717207A1 (en) | Methods of treatment employing prolonged continuous infusion of belinostat | |
| CN100553634C (zh) | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 | |
| TWI771315B (zh) | 微小奈米化藥劑及其利用 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| RU2778887C2 (ru) | Комбинация трифлуридина/типирацил гидрохлорида, противоопухолевого платинового комплекса и модулятора контрольных точек иммунного ответа | |
| JP2025505381A5 (https=) | ||
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer |